ACR Convergence 2022

Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has shown potential for the treatment of Sjögren's syndrome in a phase 2 study.

Patients with rheumatic diseases have reported issues with access to methotrexate following changes to abortion laws, show findings from a questionnaire study conducted in the USA.

Researchers have found that secukinumab performs equally well to adalimumab biosimilar for the treatment of radiographic axial spondyloarthritis in a head-to-head trial.

Researchers have developed the ILD-RISC score, which has the potential to predict the development of interstitial lung disease in patients with systemic sclerosis.

The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.

Peresolimab, a PD-1 receptor agonist, may represent a promising approach to treating rheumatoid arthritis, with an “encouraging” safety profile, suggests research reported at the ACR Convergence 2022 in Philadelphia, Pennsylvania, USA.

A diet and exercise program delivered in community settings may improve some clinical outcomes for people with knee osteoarthritis and overweight or obesity, suggest findings from the WE-CAN pragmatic randomized controlled trial.

COVID-19 vaccination should be actively promoted for women with rheumatic and musculoskeletal diseases who are pregnant or planning a pregnancy, say researchers.

Discontinuation of mycophenolate mofetil for at least 10 days is associated with an improved antibody response to COVID-19 vaccination among people with rheumatic diseases, research suggests.

Early trial results suggest that ultrasound-guided genicular nerve block may represent a promising short-term treatment option for pain associated with knee osteoarthritis.